TNF and ovarian carcinoma: DEX can inhibit the surgical stress response and the release of stress mediators, promote the recovery of NK cell activity, and reduce the level of TNF-α, so it can be used as an effective immunomodulatory drug for patients with ovarian cancer during the perioperative period (Shin et al., 2021).